A Contrarian View Of MedImmune V. Genentech

Law360, New York (February 7, 2007, 12:00 AM EST) -- The Supreme Court's eagerly anticipated January 9 decision in MedImmune v. Genentech has led to the usual crush of commentary. Many lawyers rushed to proclaim it a significant reversal of established patent law resulting in the death of the principle of “licensee estoppel.”

They foretold radical changes in the relationships between licensors and licensees that would upset settled expectations and lead to greatly increased litigation, the code word for chaos. In the words of the apt Gershwin tune, “It ain’t necessarily so.”

The sky is not...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.